Artivion (NYSE:AORT) SVP Jean Holloway Sells 6,394 Shares of Stock

Artivion, Inc. (NYSE:AORT) SVP Jean Holloway sold 6,394 shares of the firm’s stock in a transaction dated Monday, November 17th. The stock was sold at an average price of $45.17, for a total transaction of $288,816.98. Following the completion of the sale, the senior vice president directly owned 163,408 shares of the company’s stock, valued at approximately $7,381,139.36. The trade was a 3.77% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Artivion Trading Down 0.6%

Shares of NYSE AORT opened at $44.87 on Wednesday. The company has a debt-to-equity ratio of 0.52, a quick ratio of 3.48 and a current ratio of 4.78. The business’s 50 day moving average price is $42.77 and its 200-day moving average price is $36.66. Artivion, Inc. has a fifty-two week low of $21.97 and a fifty-two week high of $48.04. The company has a market cap of $2.13 billion, a price-to-earnings ratio of -106.83 and a beta of 1.65.

Artivion (NYSE:AORT) last posted its quarterly earnings data on Thursday, November 6th. The company reported $0.16 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.14 by $0.02. Artivion had a positive return on equity of 5.70% and a negative net margin of 4.43%.The company had revenue of $113.39 million during the quarter, compared to analysts’ expectations of $110.71 million. The company’s revenue was up 18.9% on a year-over-year basis. Artivion has set its FY 2025 guidance at EPS. On average, sell-side analysts expect that Artivion, Inc. will post 0.37 earnings per share for the current year.

Institutional Trading of Artivion

Hedge funds have recently bought and sold shares of the stock. Invesco Ltd. grew its position in shares of Artivion by 27.9% in the 1st quarter. Invesco Ltd. now owns 341,656 shares of the company’s stock worth $8,398,000 after buying an additional 74,589 shares during the last quarter. Oppenheimer Asset Management Inc. purchased a new stake in Artivion during the second quarter valued at approximately $669,000. Fred Alger Management LLC acquired a new stake in Artivion in the first quarter valued at approximately $2,969,000. Diker Management LLC purchased a new position in Artivion in the first quarter worth $369,000. Finally, Atria Investments Inc acquired a new position in shares of Artivion during the second quarter worth $244,000. Hedge funds and other institutional investors own 86.37% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently commented on AORT. Wall Street Zen raised shares of Artivion from a “buy” rating to a “strong-buy” rating in a research note on Saturday. LADENBURG THALM/SH SH downgraded shares of Artivion from a “buy” rating to a “neutral” rating and lifted their price target for the company from $32.00 to $38.80 in a research note on Wednesday, August 13th. Oppenheimer reiterated an “outperform” rating and issued a $50.00 price target on shares of Artivion in a report on Friday, November 7th. Stifel Nicolaus increased their price objective on Artivion from $40.00 to $46.00 and gave the stock a “buy” rating in a research note on Monday, September 29th. Finally, Citizens Jmp lifted their target price on Artivion from $47.00 to $53.00 and gave the company a “market outperform” rating in a research report on Friday, November 7th. Seven investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Artivion presently has an average rating of “Moderate Buy” and a consensus target price of $49.11.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.